samedan logo
 
 
spacer
home > pmps > winter 2017 > working together
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Working Together

If the pharmaceutical supply chain was a living, breathing creature, it would probably be the microscopic water flea. Daphnia pulex was the first crustacean to have its genome sequenced, and results showed that it has 31,000 genes – 25% more than us humans. Just like the genetic complexity of the water flea was a challenge for scientists, the sophisticated pharma supply chain is now changing the way the industry operates.

The rise of emerging markets and the different geographic standards used around the world are additional challenges that manufacturers need to address. As always in the pharma sector, the complex regulatory landscape has a significant impact on companies. This includes widely recognised guidelines such as those from the FDA and their European counterparts, as well as client standards and environmental legislation. All of these factors are contributing to making the supply chain nearly impossible to navigate.

Current Situation

As new markets and technologies emerge in the pharma field, manufacturers are starting to feel the pressure of working with a higher number of suppliers, partners and distributors. They often produce drugs for pharmacies or specific patients, rather than wholesale – this means that the industry is starting to be driven by demand rather than forecast. The medicines themselves are becoming progressively complex and bespoke, meaning that the production of mini batches or personalised medicine is another rising trend.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Darren Halford is Sales Director at obsolete components supplier EU Automation. Previously, he has worked as a recruitment consultant, recommending new employment opportunities to senior construction professionals. Darren oversees all sales and service operations and has been with the company since its inception in May 2009.
spacer
Darren Halford
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) With EC Authorisation of Bispecific Antibody for the Treatment of Patients With Multiple Myeloma

BEERSE, BELGIUM, 24 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI®▼ (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.1 Today’s milestone marks the first approval worldwide for teclistamab, a bispecific antibody that redirects CD3-positive T-cells to B-cell maturation antigen (BCMA)-expressing myeloma cells to induce the killing of tumour cells.1
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement